{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.27","upperLimit":"51.10","value":"25.6"},{"groupId":"OG001","lowerLimit":"15.94","upperLimit":"63.31","value":"40.0"}]}],"title":"12 Months"},{"categories":[{"measurements":[{"comment":"NA indicated survival rate not reached for 24 months at this DCO.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"9.74","upperLimit":"53.67","value":"30.0"}]}],"title":"24 Months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Survival rates were defined as the Kaplan-Meier estimate of OS at 12 and 24 months.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants with osteosarcoma and Ewing sarcoma, rhabdomyosarcoma, non rhabdomyosarcoma soft tissue sarcoma, and other sarcomas were included in this arm. Participants were administered durvalumab 30 mg/kg IV in combination with tremelimumab 1 mg/kg IV in Cycles 1-4 every 28 days. From Cycle 5 onwards participants were administered durvalumab 30 mg/kg every 28 days until clinical or confirmed disease progression or until any of other discontinuation criterion was met, whichever occurred first.","id":"OG000","title":"SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg"},{"description":"Participants with solid tumor other (STO) were included in this arm. Participants were administered durvalumab 30 mg/kg IV in combination with tremelimumab 1 mg/kg IV in Cycles 1-4 every 28 days. From Cycle 5 onwards participants were administered durvalumab 30 mg/kg every 28 days until clinical or confirmed disease progression or until any of other discontinuation criterion was met, whichever came occurred first.","id":"OG001","title":"STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg"}],"paramType":"NUMBER","populationDescription":"The FAS included all participants who were assigned to treatment and received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"At 12 and 24 Weeks","title":"Dose-Expansion Phase Only: Survival Rate at 12 Months and 24 Months","type":"PRIMARY","unitOfMeasure":"percentage of participants"}